Overview A Phase I Study to Evaluate LSALT Peptide Status: Completed Trial end date: 2020-03-31 Target enrollment: Participant gender: Summary A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants Phase: Early Phase 1 Details Lead Sponsor: Arch Biopartners Inc.